Sale of unaffected batches of Medicube capsule cream can resume: HSA
Minute amounts of the banned Sudan IV dye were found in two samples of Medicube PDRN Pink Collagen Capsule Cream sold by Venus Beauty.
The Health Sciences Authority (HSA) in Singapore has announced that sales of the affected batches of Medicube PDRN Pink Collagen Capsule Cream, which contained minute traces of the Sudan IV dye, may resume. The HSA had previously directed three companies - APR SG, Venus Beauty and Rirora International - to halt sales following tests that detected the Sudan IV dye in two samples sold by Venus Beauty.
The companies Rirora International and APR SG may resume sales of their unaffected batches, according to the HSA. The Sudan IV dye is not permitted for use in cosmetic products due to its carcinogenic effects and potential genotoxicity. The affected batches are batch numbers 2E122I.2E117I and 2E191G.2E193G. Consumers who have concerns regarding refunds should contact the seller.
The HSA will continue to monitor the situation closely. Individuals found supplying cosmetic products with prohibited ingredients face penalties including fines up to S$50,000 and imprisonment.
Written by urgent.news from Channel News Asia's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Sale of unaffected batches of Medicube capsule cream can resume: HSA channelnewsasia.com
